1. Do RARA/PML fusion gene deletions confer resistance to ATRA-based therapy in patients with acute promyelocytic leukemia? Subramaniyam, Shivakumar; Nandula, Subhadra; Nichols, G.; Weiner, Michael A.; Satwani, Prakash; Alobeid, Bachir; Bhagat, Govind; Vundavalli, Murty V. 2006 Articles LeukemiaLeukemia--TreatmentDrug resistance in cancer cellsGene fusionGenetics